Meta-analysis of primary care delivered buprenorphine treatment retention outcomes

• Published in: The American journal of drug and alcohol abuse 2023-11, Vol.49 (6), p.756-765
• Main Authors: Cooper, Robert L, Edgerton, Ryan D, Watson, Julia, Conley, Nicholas, Agee, William A, Wilus, Derek M, MacMaster, Samuel A, Bell, Lisa, Patel, Parul, Godbole, Amruta, Bass-Thomas, Cynthia, Ramesh, Aramandla, Tabatabai, Mohammad
• Format: Article
• Language: English
• Subjects: Attrition; Buprenorphine; Efficacy; Meta-analysis; Opioids; Primary care; Race; Random effects; Retention; Substance use disorder
• ISSN: 0095-2990; 1097-9891; 1097-9891
• DOI: 10.1080/00952990.2023.2251653

Currently, the capacity to provide buprenorphine treatment (BT) is not sufficient to treat the growing number of people in the United States with opioid use disorder (OUD). We sought to examine participant retention in care rates of primary care delivered BT programs and to describe factors associated with retention/attrition for participants receiving BT in this setting. A PRISMA-guided search of various databases was performed to identify the articles focusing on efficacy of BT treatment and OUD. A systematic literature search identified 15 studies examining retention in care in the primary care setting between 2002 and 2020. Random effects meta-regression were used to identify retention rates across studies. Retention rates decreased across time with a mean 0.52 rate at one year. Several factors were found to be related to retention, including: race, use of other drugs, receipt of counseling, and previous treatment with buprenorphine. While we only investigate BT through primary care, our findings indicate retention rates are equivalent to the rates reported in the specialty care literature. More work is needed to examine factors that may impact primary care delivered BT specifically and differentiate participants that may benefit from care delivered in specialty over primary care as well as the converse.